Top image

Our Research

Here you'll find information about our Flagship programs and other projects. Use the filters below to display research of interest using one of the three categories.
  • T1 | Flagship 3 Scholarships & Awards
    Thomas Johnson: YB-1: A central player in carcinogenesis and malignant behaviour of malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive, asbestos-induced malignancy that responds poorly to treatment. The combination of cisplatin and pemetrexed, which is the current standard...
  • T2,T3 | Flagship 3 Scholarships & Awards
    Peey Sei Kok: What are good surrogates for clinically meaningful benefit of new oncology therapies in advanced cancers?
    Robust surrogate endpoints have the potential to reduce the clinical, economic and time burden associated with conducting RCTs and drug development. Our work will feed into future collaborative...
    Phase i/ii clinical trialPhase iii clinical trialDrug developmentClinical Trials
  • T2,T3 | Flagship 3 Scholarships & Awards
    Mohsen Shafiei: Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: A Prospective Observational Study
    The aim of this research project is to determine and compare and pharmacokinetics (PK) of capecitabine and its metabolites in older and younger adults with cancer, and the correlation between ...
    Prospective observational studyDrug developmentTreatment
  • T1,T2 | Flagship 3 Scholarships & Awards
    Morghan Lucas: Seeing is believing: Mapping and targeting the extracellular matrix in pancreatic cancer
    This project will comprehensively chart for the first time the extracellular matrix (ECM) landscape of human pancreatic cancer to deepen our understanding of the role of the ECM in cancer prog...
    BiomarkersNew therapies and diagnosticsPancreatic cancer
  • T1,T2,T3 | Flagship Completed Prior June 2016
    Sydney Catalyst Scholarships Awarded pre July 2016
    We aim to encourage training and development of outstanding researchers and clinicians from within Sydney Catalyst units, who have the potential to develop highly significant ca...
  • T1 | Flagship Completed Prior June 2016
    Lorraine Chantrill and team: IMPACT Trial
    Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) aimed to improve outcomes for patients with advanced pancreas cancer by using molecular analysis of tumor tissue to guide treatment ...
    Personalised medicineClinical TrialsPancreatic cancerTreatment
  • T1 | Sydney Catalyst Supported
    David Croucher: Mapping and manipulating therapeutically induced JNK network architecture to tackle breast cancer chemoresistance
    The current generation of cancer therapies mostly target components of signalling pathways, being either small molecule inhibitors or monoclonal antibodies to cell surface receptors. It is fas...
    Breast CancerChemo resistance
  • T2,T3 | Sydney Catalyst Supported
    Phyllis Butow & team: A sustainable and supported clinical pathway for managing anxiety and depression in cancer patients: Developing and evaluating components and testing implementation strategies
    Anxiety and depression are common in those diagnosed with cancer, causing suffering to individuals and their families and potentially increasing health services usage and decreasing adherence ...
    PsychosocialPsychologyEvidence-based practiceClinical TrialsAnxietyDepression
  • T1 | Sydney Catalyst Supported
    CINSW RIGs and REGs
    The CINSW Research Equipment and Infrastructure Grants Program is directed to providing substantial funding for key research platforms, core equipment and capacities to enhance the cancer rese...
    Research EquipmentResearch InfrastructureCINSW
  • T2,T3 | Flagship Completed Prior June 2016
    David Barnes and Team: Lung Cancer Demonstration Project
    Cancer Australia engaged four demonstration sites (in four States) to conduct projects that would address five principles of breast practice lung cancer care. Sydney Local Health District part...
    Implementation researchLung cancerMDT